Clinical Service Line 08 - Acute Medicine, ED, Ambulatory Care, Acute Medical, SAU

Permanent URI for this collection

https://hdl.handle.net/20.500.12847/33

Browse

Recent Submissions

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Neurosarcoidosis with chronic cough and Horner's syndrome
    (2024) Callanan, E; Mcnamara, P; Ingle, G
    Abstract A 62-year-old man attended ophthalmology for a simple ptosis repair. He had a chronic cough, a Horner's syndrome with post-gustatory hyperhidrosis. He was referred to the respiratory and neurology teams. MR scan of his head and neck found evidence of multifocal disease at the skull base and carotid canal, and further tests identified additional deposits in the hilar lymph nodes, heart and sacrum. A transbronchial biopsy confirmed the diagnosis of sarcoidosis. His symptoms and imaging responded well to corticosteroids, but he still undergoes regular imaging. We discuss the features of Horner's syndrome, and the autonomic associations of a chronic cough. Keywords: AUTONOMIC; CLINICAL NEUROLOGY; NEUROANATOMY; RESPIRATORY MEDICINE. © Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ. PubMed Disclaimer Conflict of interest statement Competing interests: None declared. Publication types Case Reports MeSH terms Central Nervous System Diseases* Chronic Cough Horner Syndrome* / complications Horner Syndrome* / diagnostic imaging Humans Male Middle Aged Sarcoidosis* / complications Sarcoidosis* / diagnostic imaging Supplementary concepts Neurosarcoidosis Related information MedGen LinkOut - more resources Full Text Sources HighWire Ovid Technologies, Inc. Medical MedlinePlus Health Information
  • No Thumbnail Available
    Item
    Intravitreal Fluocinolone Acetonide Implant (ILUVIEN®) for the Treatment of Retinal Conditions. A Review of Clinical Studies
    (2023) Mushtaq, Y; Mushtaq, M.M.; Gatzioufas, Z.; Ripa, M.; Motta, L.; Panos, G.D.
    Fluocinolone acetonide (FAc) intravitreal implant (Iluvien®) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non–infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non-biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders.
  • No Thumbnail Available
    Item
    Intravitreal fluocinolone acetonide implant (ILUVIEN) for the treatment of retinol conditions. A review of clinical studies.
    (2023) Mushtaq, Y; Mushtaq, M.M; Gatzioufas, Z; Ripa, M; Motta, L; Panos, G.D
    Fluocinolone acetonide (FAc) intravitreal implant (Iluvien®) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non–infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non-biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders.
  • No Thumbnail Available
    Item
    Intravitreal fluocinolone acetonide implant (ILUVIEN®) for the treatment of retinal conditions. A review of clinical studies
    (2023) Mushtaq, Y; Mushtaq, M.M; Gatzioufas, Z; Ripa, M; Motta, L; Panos, G.D
    Fluocinolone acetonide (FAc) intravitreal implant (Iluvien®) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non-infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non-biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders. Keywords: Iluvien; diabetic macular oedema; intravitreal implant; posterior uveitis; retinal vein occlusion; steroid implant. © 2023 Mushtaq et al. PubMed Disclaimer